Ariadne Bio is addressing a major unmet need in Parkinson’s disease and aging more generally: apathy and loss of motivation, which drive disability, caregiver burden, and institutionalization yet have no approved treatments. Current options either target motor symptoms, blunt emotion without restoring drive, or pose safety risks that make them unsuitable for older adults. 
Ariadne’s solution is AB-300, a first-in-class, non-hallucinogenic serotonergic therapy designed to directly restore motivation and goal-directed behavior by modulating serotonergic and pathways implicated in motivation. AB-300 is engineered for chronic, outpatient use for the treatment of Parkinson’s disease–related apathy, with clear expansion potential into broader neurodegenerative and aging-associated motivational disorders.

Ariadne Bio

Org chart

Teams

Offices

Ariadne Bio

Org chart

Teams

Offices

Related companies